Ovid Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ovid Therapeutics, Inc.
Seeing significant unmet medical needs and insufficiently met needs in narcolepsy and rare types of epilepsy, Takeda has shifted its neuroscience focus.
Revising the two companies’ 2017 epilepsy collaboration, Takeda will take over Phase III development and commercialization of soticlestat. Ovid gets $196m up front, and it can shift focus.
Putting aside the coronavirus pandemic for a while, and turning to industry’s more bread and butter R&D activities, Scrip takes a look at the industry’s biggest clinical trial hits and misses of the year.
2020 has kicked off with a major European biotech deal that will see the Italian conglomerate Angelini take over Switzerland's Arvelle which is on the verge of getting EU approval for an anti-epilepsy drug licensed from SK Bio that got the green light in the US two years ago.